Atenolol (Page 4 of 6)
Acute Myocardial Infarction
In a series of investigations in the treatment of acute myocardial infarction, bradycardia and hypotension occurred more commonly, as expected for any beta blocker, in atenolol-treated patients than in control patients. However, these usually responded to atropine and/or to withholding further dosage of atenolol. The incidence of heart failure was not increased by atenolol. Inotropic agents were infrequently used. The reported frequency of these and other events occurring during these investigations is given in the following table.
In a study of 477 patients, the following adverse events were reported during either intravenous and/or oral atenolol administration:
Conventional TherapyPlus Atenolol(n=244) | ConventionalTherapy Alone(n=233) | |||
Bradycardia | 43 | (18%) | 24 | (10%) |
Hypotension | 60 | (25%) | 34 | (15%) |
Bronchospasm | 3 | (1.2%) | 2 | (0.9%) |
Heart Failure | 46 | (19%) | 56 | (24%) |
Heart Block | 11 | (4.5%) | 10 | (4.3%) |
BBB + MajorAxis Deviation | 16 | (6.6%) | 28 | (12%) |
Supraventricular Tachycardia | 28 | (11.5%) | 45 | (19%) |
Atrial Fibrillation | 12 | (5%) | 29 | (11%) |
Atrial Flutter | 4 | (1.6%) | 7 | (3%) |
Ventricular Tachycardia | 39 | (16%) | 52 | (22%) |
Cardiac Reinfarction | 0 | (0%) | 6 | (2.6%) |
Total Cardiac Arrests | 4 | (1.6%) | 16 | (6.9%) |
Nonfatal Cardiac Arrests | 4 | (1.6%) | 12 | (5.1%) |
Deaths | 7 | (2.9%) | 16 | (6.9%) |
Cardiogenic Shock | 1 | (0.4%) | 4 | (1.7%) |
Development of VentricularSeptal Defect | 0 | (0%) | 2 | (0.9%) |
Development of MitralRegurgitation | 0 | (0%) | 2 | (0.9%) |
Renal Failure | 1 | (0.4%) | 0 | (0%) |
Pulmonary Emboli | 3 | (1.2%) | 0 | (0%) |
In the subsequent International Study of Infarct Survival (ISIS-1) including over 16,000 patients of whom 8,037 were randomized to receive atenolol treatment, the dosage of intravenous and subsequent oral atenolol was either discontinued or reduced for the following reasons:
Reasons for Reduced Dosage IV Atenolol Reduced Dose(< 5 mg)* | Oral PartialDose | |||
| ||||
Hypotension / Bradycardia | 105 | (1.3%) | 1168 | (14.5%) |
Cardiogenic Shock | 4 | (.04%) | 35 | (.44%) |
Reinfarction | 0 | (0%) | 5 | (.06%) |
Cardiac Arrest | 5 | (.06%) | 28 | (.34%) |
Heart Block (> first degree) | 5 | (.06%) | 143 | (1.7%) |
Cardiac Failure | 1 | (.01%) | 233 | (2.9%) |
Arrhythmias | 3 | (.04%) | 22 | (.27%) |
Bronchospasm | 1 | (.01%) | 50 | (.62%) |
During postmarketing experience with atenolol, the following have been reported in temporal relationship to the use of the drug: elevated liver enzymes and/or bilirubin, hallucinations, headache, impotence, Peyronie’s disease, postural hypotension which may be associated with syncope, psoriasiform rash or exacerbation of psoriasis, psychoses, purpura, reversible alopecia, thrombocytopenia, visual disturbance, sick sinus syndrome, and dry mouth. Atenolol, like other beta blockers, has been associated with the development of antinuclear antibodies (ANA), lupus syndrome, and Raynaud’s phenomenon.
POTENTIAL ADVERSE EFFECTS
In addition, a variety of adverse effects have been reported with other beta-adrenergic blocking agents, and may be considered potential adverse effects of atenolol.
All MedLibrary.org resources are included in as near-original form as possible, meaning that the information from the original provider has been rendered here with only typographical or stylistic modifications and not with any substantive alterations of content, meaning or intent.